Payment overview · 2025
General Payments
$2,167.66
117 reported records · 28 companies
Healthcare provider profile · identity verified
Randolph Pinto, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, CO · NPI 1285619411
Verified facts
What the public records show
CMS Open Payments records show Randolph Pinto, M.D. received $2,167.66 in general payments during 2025 across 117 reported records.
ABBVIE INC. accounted for 11.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Paxlovid, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $243.92 | 11.2% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $235.05 | 10.8% | 24 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $215.22 | 9.9% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $196.79 | 9.1% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $138.06 | 6.4% | 10 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $108.75 | 5.0% | 4 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $99.75 | 4.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.37 | 3.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.47 | 3.8% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $81.34 | 3.8% | 5 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $75.03 | 3.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $74.24 | 3.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $73.93 | 3.4% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $66.61 | 3.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.55 | 2.3% | 2 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.24 | 2.1% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $37.91 | 1.8% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $34.18 | 1.6% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.61 | 1.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.21 | 1.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.21 | 1.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.40 | 1.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.01 | 1.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.12 | 1.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.48 | 0.8% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.87 | 0.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.56 | 0.8% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $13.78 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,167.66 | 117 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $191.09 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $170.00 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $169.51 | 18 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $144.84 | 15 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $127.42 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $114.27 | 11 | 2025 |
Source payment records
|
|||||
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $113.43 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $108.50 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $100.79 | 5 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $99.75 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $90.80 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $88.38 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $81.47 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $81.34 | 5 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $75.03 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $74.19 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $73.93 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $66.61 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $65.54 | 6 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $60.87 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.67 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.55 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.68 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $47.88 | 2 | 2025 |
Source payment records
|
|||||
| BAQSIMI Normalized: baqsimi |
Drug | Amphastar Pharmaceuticals, Inc. | $45.24 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $37.91 | 2 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $37.91 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $34.18 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $30.61 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 20 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 906 | 248 |
| Losartan Potassium | Losartan Potassium | 389 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 82 |
| Lisinopril | Lisinopril | 287 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 284 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 60 |
| Ezetimibe | Ezetimibe | 207 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 53 |
| Metformin Hcl Er | Metformin Hcl | 151 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 41 |
| Allopurinol | Allopurinol | 125 | 29 |
| Gabapentin | Gabapentin | 124 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 28 |
| Bupropion Xl | Bupropion Hcl | 92 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 23 |
| Omeprazole | Omeprazole | 91 | 25 |
| Famotidine | Famotidine | 75 | 19 |
| Trazodone Hcl | Trazodone Hcl | 74 | 17 |
| Sertraline Hcl | Sertraline Hcl | 71 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 27 |
| Furosemide | Furosemide | 66 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 18 |
| Montelukast Sodium | Montelukast Sodium | 59 | 12 |
| Eliquis | Apixaban | 52 | 15 |
| Synthroid | Levothyroxine Sodium | 49 | 15 |
| Simvastatin | Simvastatin | 48 | 14 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Azithromycin | Azithromycin | 41 | 36 |
| Lorazepam | Lorazepam | 41 | 19 |
| Ozempic | Semaglutide | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Estradiol | Estradiol | 40 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 19 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 12 |
| Meloxicam | Meloxicam | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Metformin Hcl | Metformin Hcl | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Alprazolam | Alprazolam | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Wegovy | Semaglutide | 19 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Toviaz | Fesoterodine Fumarate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,167.66 · 117 records | ABBVIE INC. | AIRSUPRA, AJOVY, ALVESCO, AREXVY, AUSTEDO XR, BAQSIMI, CAPLYTA, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, EVENITY, FFRct, GEMTESA, Kerendia, LEQVIO, MOUNJARO, NEXIUM, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, REZDIFFRA, SHINGRIX, SPRAVATO, Symbravo, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Veozah, WELLBUTRIN, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error